JP2014523445A5 - - Google Patents

Download PDF

Info

Publication number
JP2014523445A5
JP2014523445A5 JP2014521743A JP2014521743A JP2014523445A5 JP 2014523445 A5 JP2014523445 A5 JP 2014523445A5 JP 2014521743 A JP2014521743 A JP 2014521743A JP 2014521743 A JP2014521743 A JP 2014521743A JP 2014523445 A5 JP2014523445 A5 JP 2014523445A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
solid dispersion
composition according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014521743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523445A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/047253 external-priority patent/WO2013012959A1/en
Publication of JP2014523445A publication Critical patent/JP2014523445A/ja
Publication of JP2014523445A5 publication Critical patent/JP2014523445A5/ja
Pending legal-status Critical Current

Links

JP2014521743A 2011-07-18 2012-07-18 前立腺癌を処置するための新規な組成物及び方法 Pending JP2014523445A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161508823P 2011-07-18 2011-07-18
US61/508,823 2011-07-18
PCT/US2012/047253 WO2013012959A1 (en) 2011-07-18 2012-07-18 Novel compositions and methods for treating prostate cancer

Publications (2)

Publication Number Publication Date
JP2014523445A JP2014523445A (ja) 2014-09-11
JP2014523445A5 true JP2014523445A5 (https=) 2015-09-03

Family

ID=47558457

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014521743A Pending JP2014523445A (ja) 2011-07-18 2012-07-18 前立腺癌を処置するための新規な組成物及び方法

Country Status (8)

Country Link
US (3) US20140288037A1 (https=)
EP (1) EP2734207A4 (https=)
JP (1) JP2014523445A (https=)
CN (1) CN103813794A (https=)
AU (1) AU2012284053A1 (https=)
BR (1) BR112014001440A2 (https=)
CA (1) CA2841960A1 (https=)
WO (1) WO2013012959A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190126460A (ko) 2007-02-09 2019-11-11 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CA2770298C (en) 2008-08-13 2017-06-20 Metabasis Therapeutics, Inc. Glucagon antagonists
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
JO3754B1 (ar) 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
US9138425B2 (en) 2013-03-12 2015-09-22 Patheon Inc. Drug delivery system to increase bioavailability
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
MX2015013247A (es) * 2013-03-15 2016-11-25 Iceutica Inc Formulacion de acetato de abiraterona.
US9694005B2 (en) * 2013-04-04 2017-07-04 University Of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
CA2920317A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US10045998B2 (en) 2013-12-12 2018-08-14 Basf Se Solid form of abiraterone acetate
WO2015191900A1 (en) * 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
US9937259B2 (en) * 2014-06-27 2018-04-10 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivatives and non-covalent complexes with albumin
SG11201700849XA (en) 2014-08-07 2017-03-30 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
US11185507B2 (en) * 2014-10-08 2021-11-30 Boston Biopharm Inc. Compositions and methods for increasing the bioavailability of one or more compounds
CN105616365B (zh) * 2014-11-08 2019-04-05 山东新时代药业有限公司 一种依维莫司片剂
WO2016119742A1 (zh) * 2015-01-29 2016-08-04 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
ES2863500T3 (es) 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
WO2016172517A1 (en) * 2015-04-24 2016-10-27 Tokai Pharmaceuticals, Inc. Methods of treating prostate cancer
WO2016185485A2 (en) * 2015-05-18 2016-11-24 Msn Laboratories Private Limited Process for the preparation of n-[4-[(3-chloro-4-fluoro phenyl) amino]-7-[[(3s)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4- (dimethyl amino)-(2e)-2-butenamide (2z)-2-butenedioate (1 :2) and its polymorphs thereof
ES3063790T3 (en) 2015-06-09 2026-04-20 Lonza Sales Ag Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN106692051B (zh) * 2015-08-18 2021-01-12 南京诺瑞特医药科技有限公司 17-（3-吡啶）雄甾-4,6-二烯-3-酮的制剂
CN105055314A (zh) * 2015-09-28 2015-11-18 杭州安德科技有限公司 一种阿比特龙的口腔喷雾剂及其使用和制备方法
US10682362B2 (en) 2015-10-14 2020-06-16 Wayne State University Treatments and diagnostics for cancers
CN109125276A (zh) * 2017-06-19 2019-01-04 齐鲁制药有限公司 一种醋酸阿比特龙片剂的药物组合物及其制备方法
TWI717629B (zh) * 2017-08-28 2021-02-01 大陸商江蘇恒瑞醫藥股份有限公司 Cyp17抑制劑的藥物組合物及其製備方法
MA50189A (fr) * 2017-09-22 2021-05-19 Dispersol Technologies Llc Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
CN109956990B (zh) * 2017-12-22 2023-02-17 四川科瑞德制药股份有限公司 一种干燥哌库溴铵的方法
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
PL247245B1 (pl) * 2019-01-31 2025-06-02 Gdanski Univ Medyczny Samoemulgująca kompozycja farmaceutyczna w postaci ciekłej zawierająca jako substancję aktywną substancję leczniczą nietrwałą w środowisku wodnym
CN110917152B (zh) * 2019-02-01 2021-07-02 鲁南制药集团股份有限公司 一种cyp17抑制剂片及其制备方法
CZ2019168A3 (cs) 2019-03-20 2020-09-30 Zentiva, K.S. Farmaceutická kompozice obsahující abirateron acetát
CN110538150A (zh) * 2019-09-26 2019-12-06 湖南瑞林医药科技有限公司 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
EP4057996B1 (en) * 2019-11-14 2023-07-12 Suven Life Sciences Limited Amorphous pharmaceutical compositions of abiraterone acetate
IL297338A (en) * 2020-04-16 2022-12-01 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer
JP7320903B2 (ja) 2021-12-15 2023-08-04 湖南慧▲澤▼生物医▲薬▼科技有限公司 アビラテロン酢酸エステルを含む組成物及び使用
WO2024091899A1 (en) * 2022-10-25 2024-05-02 University Of Maryland, Baltimore Salts of galeterone and salts of next generation galeterone analogs, and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
WO1999052931A1 (fr) * 1998-04-10 1999-10-21 Mitsubishi Chemical Corporation Dispersion solide contenant un derive d'acide sialique
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
US20080249076A1 (en) * 2003-12-03 2008-10-09 Lifecycle Pharma A/S Pharmaceutical Compositions Comprising Danazol
US20060013873A1 (en) * 2004-07-16 2006-01-19 Chih-Chiang Yang Bioadhesive dosage form of steroids
US7875599B2 (en) * 2005-03-02 2011-01-25 University Of Maryland C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
WO2010089763A2 (en) * 2008-06-30 2010-08-12 Reliance Life Sciences Pvt. Ltd. Poly(n-vinyl caprolactam-co-acrylamide) microparticles for controlled release applications
WO2010091306A1 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2011017534A2 (en) * 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer

Similar Documents

Publication Publication Date Title
JP2014523445A5 (https=)
JP2009530415A5 (https=)
JP2017511344A5 (https=)
KR20160093611A (ko) 경구 투여를 위한 약물 제제의 제조 방법
JP6355645B2 (ja) 活性成分としてテトラゾール誘導体を含む、溶解性が改善された固体分散体
AU2007252994A1 (en) Pharmaceutical compositions comprising implitapide and methods of using same
US20170129869A1 (en) Amorphous form of eliglustat hemitartarate
RU2012131158A (ru) Фармацевтическая композиция с контролируемым высвобождением лекарственного средства
WO2016038532A1 (en) Amorphous treprostinil diethanolamine
TW201446286A (zh) 抗病毒化合物之固態分散調製劑
JP2014525449A5 (https=)
WO2015132708A1 (en) Pharmaceutical composition of roflumilast
CN105188676A (zh) 包括葡糖激酶活化剂的固体组合物及其制备和使用方法
JP2011507838A5 (https=)
JP2025026876A (ja) ５－ブロモピリジン－３－イル３－デオキシ－３－［４－（３，４，５－トリフルオロフェニル）－１Ｈ－１，２，３－トリアゾール－１－イル］－１－チオ－α－Ｄ－ガラクトピラノシドの非晶質形態
TW201322979A (zh) 醫藥組成物
JP2011500811A5 (https=)
WO2016193779A1 (en) Oral pharmaceutical composition of isotretinoin
JP2019516765A5 (https=)
RU2015141792A (ru) Сухие фармацевтические композиции, включающие наночастицы активного агента, связанные с частицами носителя
JP2009510027A (ja) ベンラファキシン塩酸塩の制御放出性の医薬組成物、及びその調製方法
WO2011113320A1 (zh) 包含决奈达隆的药物组合物
CN104800184A (zh) 琥珀酸呋罗曲坦缓释剂片
TWI837095B (zh) 一種醫藥組成物及其製備方法
JP2015086194A (ja) ラベプラゾールナトリウム含有粒子の製造方法及びそれを含む医薬組成物